Recombinant human DNase (rhDNase) in cystic fibrosis: is it cost effective?
Conway
S P
SP
Regional Paediatric Unit, St James' and Seacroft Hospitals, Leeds.
D000900:Anti-Bacterial Agents / Q000191:economics; D002648:Child; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000628:therapy*; D003850:Deoxyribonuclease I / Q000191:economics* / Q000627:therapeutic use; D005100:Expectorants / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007902:Length of Stay; D010343:Patient Admission; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005100:Expectorants; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I